Simulations Plus, Inc. is a provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. It operates through two segments: software and services. The Companyâs business units include cheminformatics, physiologically based pharmacokinetics, clinical pharmacology and pharmacometrics, quantitative systems pharmacology, adaptive learning & insights and medical communications. The Company operates in biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry. It delivers simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Its cutting-edge technology is licensed and utilized by pharmaceutical, biotechnology, and regulatory agencies worldwide.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļSLP
āļāļ·āđāļāļāļĢāļīāļĐāļąāļSimulations Plus Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJun 18, 1997
āļāļĩāļāļĩāđāļMr. Shawn M. O'Connor
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ243
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļJun 18
āļāļĩāđāļāļĒāļđāđ800 Park Offices Drive, Suite 401
āđāļĄāļ·āļāļRESEARCH TRIANGLE PARK
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ Global Select Consolidated
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ27709
āđāļāļĢāļĻāļąāļāļāđ16617237723
āđāļ§āđāļāđāļāļāđhttps://www.simulations-plus.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļSLP
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJun 18, 1997
āļāļĩāļāļĩāđāļMr. Shawn M. O'Connor
Dr. Hon. Walter S. Woltosz
Dr. Hon. Walter S. Woltosz
Independent Director
Ms. Jill Fiedler-Kelly
Interim President - Services Solutions
Interim President - Services Solutions
Ms. Sharlene Evans
Independent Director
Dr. John Kenneth Paglia, Ph.D.
Dr. John Kenneth Paglia, Ph.D.
Independent Director
Mr. Erik Guffrey
Co-Chief Product and Technology Officer
Co-Chief Product and Technology Officer
Mr. Josh Fohey
Chief Operating Officer
Mr. Shawn M. O'Connor
Chief Executive Officer
Mr. Steven Chang
Global Head - Strategic Alliances
Global Head - Strategic Alliances
Mr. John A. Dibella
Chief Revenue Officer
Ms. Jenna Rouse
Global Head - Clinical Operations
Global Head - Clinical Operations
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. Hon. Walter S. Woltosz
Dr. Hon. Walter S. Woltosz
Independent Director
Ms. Jill Fiedler-Kelly
Interim President - Services Solutions
Interim President - Services Solutions
Ms. Sharlene Evans
Independent Director
Dr. John Kenneth Paglia, Ph.D.
Dr. John Kenneth Paglia, Ph.D.
Independent Director
Mr. Erik Guffrey
Co-Chief Product and Technology Officer
Co-Chief Product and Technology Officer
Mr. Josh Fohey
Chief Operating Officer
SPDR FactSet Innovative Technology ETF
First Trust Active Factor Small Cap ETF
Invesco Nasdaq Free Cash Flow Achievers ETF
Franklin Exponential Data ETF
WisdomTree Artificial Intelligence and Innov Fund
Invesco S&P SmallCap Health Care ETF
First Trust Multi-Manager Small Cap Opportunities ETF
JPMorgan Diversified Return U.S. Small Cap Equity ETF
WisdomTree US SmallCap Quality Growth Fund
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
SPDR FactSet Innovative Technology ETF
āļŠāļąāļāļŠāđāļ§āļ0.57%
First Trust Active Factor Small Cap ETF
āļŠāļąāļāļŠāđāļ§āļ0.31%
Global X HealthTech ETF
āļŠāļąāļāļŠāđāļ§āļ0.3%
Invesco Nasdaq Free Cash Flow Achievers ETF
āļŠāļąāļāļŠāđāļ§āļ0.3%
Franklin Exponential Data ETF
āļŠāļąāļāļŠāđāļ§āļ0.28%
WisdomTree Artificial Intelligence and Innov Fund
āļŠāļąāļāļŠāđāļ§āļ0.22%
Invesco S&P SmallCap Health Care ETF
āļŠāļąāļāļŠāđāļ§āļ0.2%
First Trust Multi-Manager Small Cap Opportunities ETF
āļŠāļąāļāļŠāđāļ§āļ0.13%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
āļŠāļąāļāļŠāđāļ§āļ0.1%
WisdomTree US SmallCap Quality Growth Fund
āļŠāļąāļāļŠāđāļ§āļ0.1%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
23.51M
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē
SLP.NB Interim Cash Dividend of gross USD 0.06 paid on Aug 05, 2024 going ex on Jul 29, 2024
SLP.NB Interim Cash Dividend of gross USD 0.06 paid on May 06, 2024 going ex on Apr 26, 2024
SLP.NB Interim Cash Dividend of gross USD 0.06 paid on Feb 05, 2024 going ex on Jan 26, 2024
SLP.NB Final Cash Dividend of gross USD 0.06 paid on Nov 06, 2023 going ex on Oct 27, 2023
SLP.NB Interim Cash Dividend of gross USD 0.06 paid on Aug 07, 2023 going ex on Jul 28, 2023
SLP.NB Interim Cash Dividend of gross USD 0.06 paid on May 01, 2023 going ex on Apr 21, 2023
SLP.NB Interim Cash Dividend of gross USD 0.06 paid on Feb 06, 2023 going ex on Jan 27, 2023
SLP.NB Final Cash Dividend of gross USD 0.06 paid on Nov 07, 2022 going ex on Oct 28, 2022
SLP.NB Interim Cash Dividend of gross USD 0.06 paid on Aug 01, 2022 going ex on Jul 22, 2022
SLP.NB Interim Cash Dividend of gross USD 0.06 paid on May 02, 2022 going ex on Apr 22, 2022
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ